Montserrat Muoz

List of Publications by Year in Descending Order

98 papers	3,672 citations	35 h-index	59 g-index
108 ext. papers	4,531 ext. citations	7 avg, IF	4.61 L-index

#	Paper	IF	Citations
98	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors-Integrating electronic data collection into clinical practice. *Cancer Research*, **2022**, 82, P4-11-28-P4-11-28	10.1	
97	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. *Cancer Research*, **2022**, 82, P4-10-04-P4-10-04	10.1	0
96	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. *Cancer Research*, **2022**, 82, P4-07-08-P4-07-08	10.1	0
95	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.. *European Journal of Cancer*, **2022**, 168, 12-24	7.5	1
94	Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.. *PLoS ONE*, **2022**, 17, e0265127	3.7	1
93	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. *Journal of Clinical Oncology*, **2021**, 39, 3060-3060	2.2	
92	CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.. *Journal of Clinical Oncology*, **2021**, 39, 1014-1014	2.2	
91	Gene expression profiles of breast cancer metastasis according to organ site. *Molecular Oncology*, **2021**,	7.9	3
90	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. *Clinical Cancer Research*, **2021**, 27, 3116-3125	12.9	3
89	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. *Npj Breast Cancer*, **2021**, 7, 8	7.8	2
88	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. *EBioMedicine*, **2021**, 69, 103451	8.8	3
87	Trajectories of alcohol consumption during life and the risk of developing breast cancer. *British Journal of Cancer*, **2021**, 125, 1168-1176	8.7	0
86	Implementing preoperative endocrine therapy in breast cancer. *Lancet Oncology, The*, **2020**, 21, 1390-1392	12.7	
85	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. *Breast Cancer Research*, **2020**, 22, 45	8.3	55
84	Phase III study to evaluate patients' preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). *European Journal of Cancer Care*, **2020**, 29, e13253	2.4	1
83	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2020**, 84, 101965	14.4	39
82	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nature Communications*, **2020**, 11, 385	17.4	36

81	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 33-43	21.7	52
80	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. *Cancers*, **2020**, 12,	6.6	9
79	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. *Scientific Reports*, **2020**, 10, 7741	4.9	4
78	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncology, The*, **2020**, 21, 1455-1464	21.7	20
77	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. *Nutrients*, **2020**, 12,	6.7	2
76	Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial. *Journal of Human Nutrition and Dietetics*, **2019**, 32, 468-479	3.1	5
75	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. *Breast Cancer Research and Treatment*, **2019**, 177, 115-125	4.4	7
74	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 303	5.3	3
73	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. *Scientific Reports*, **2019**, 9, 3904	4.9	12
72	Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q". *Health and Quality of Life Outcomes*, **2019**, 17, 143	3	2
71	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. *European Journal of Radiology*, **2019**, 117, 132-139	4.7	6
70	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. *Environment International*, **2019**, 122, 389-399	12.9	12
69	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. *BMC Medicine*, **2019**, 17, 8	11.4	15
68	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER breast cancer. *Nature Cell Biology*, **2018**, 20, 211-221	23.4	71
67	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. *Cancer Treatment Reviews*, **2018**, 67, 63-70	14.4	45
66	Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors. *European Journal of Cancer Care*, **2018**, 27, e12861	2.4	13
65	Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) □ pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.. *Journal of Clinical Oncology*, **2018**, 36, 1013-1013	2.2	5
64	A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. *Journal of Clinical Oncology*, **2018**, 36, TPS1114-TPS1114	2.2	2

63	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. *Journal of Clinical Oncology*, **2018**, 36, 1521-1521	2.2	
62	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 545-554	21.7	175
61	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. *Cancer Research*, **2017**, 77, 2213-2221	10.1	109
60	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. *Clinical Cancer Research*, **2017**, 23, 3035-3044	12.9	17
59	Physical activity and breast cancer risk by pathological subtype. *Gynecologic Oncology*, **2017**, 144, 577-585	4.9	27
58	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. *Oncotarget*, **2017**, 8, 73144-73153	3.3	19
57	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. *Journal of Clinical Oncology*, **2017**, 35, 3030-3038	2.2	65
56	MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells. *Oncotarget*, **2017**, 8, 83384-83406	3.3	16
55	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. *Oncologist*, **2017**, 22, 1301-1308	5.7	10
54	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. *Clinical and Translational Oncology*, **2017**, 19, 341-356	3.6	5
53	Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).. *Journal of Clinical Oncology*, **2017**, 35, 1023-1023	2.2	4
52	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. *Oncotarget*, **2017**, 8, 21930-21937	3.3	10
51	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. *JAMA Oncology*, **2016**, 2, 1287-1294	13.4	65
50	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. *Journal of Clinical Oncology*, **2016**, 34, 3033-3033	2.2	
49	Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.. *Journal of Clinical Oncology*, **2016**, 34, e12504-e12504	2.2	
48	Ingested Nitrate and Breast Cancer in the Spanish Multicase-Control Study on Cancer (MCC-Spain). *Environmental Health Perspectives*, **2016**, 124, 1042-9	8.4	15
47	The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. *PLoS ONE*, **2016**, 11, e0159672	3.7	17
46	SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). *Clinical and Translational Oncology*, **2016**, 18, 1229-1236	3.6	39

45	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. *Journal of the Academy of Nutrition and Dietetics*, **2016**, 116, 1914-1924.e6	3.9	15
44	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. *Journal of Clinical Oncology*, **2015**, 33, 1045-52	2.2	97
43	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. *Journal of Clinical Oncology*, **2015**, 33, 3788-95	2.2	43
42	Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*, **2015**, 24 Suppl 2, S26-35	3.6	450
41	Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. *Oncologist*, **2015**, 20, 111-2	5.7	15
40	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. *BMC Medicine*, **2015**, 13, 303	11.4	87
39	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. *PLoS ONE*, **2015**, 10, e0126096	3.7	39
38	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. *Breast Cancer Research and Treatment*, **2014**, 143, 507-15	4.4	46
37	Trastuzumab in small tumours and in elderly women. *Cancer Treatment Reviews*, **2014**, 40, 41-7	14.4	14
36	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. *Breast*, **2014**, 23, 710-20	3.6	31
35	Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. *Cell Reports*, **2014**, 6, 514-27	10.6	194
34	Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. *Critical Reviews in Oncology/Hematology*, **2014**, 89, 62-72	7	34
33	Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. *Medical Oncology*, **2014**, 31, 783	3.7	36
32	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. *Journal of Clinical Oncology*, **2014**, 32, 11107-11107	2.2	
31	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. *Journal of Clinical Oncology*, **2014**, 32, 1602-1602	2.2	
30	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2013**, 13, 381-91	2.2	14
29	Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. *Journal of Clinical Oncology*, **2013**, 31, 2593-9	2.2	45
28	Infrequent loss of luminal differentiation in ductal breast cancer metastasis. *PLoS ONE*, **2013**, 8, e78097	3.7	5

27	Circulating levels of HER-2/neu oncoprotein in breast cancer. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 5-21	5.9	24
26	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncology, The*, **2011**, 12, 369-76	21.7	68
25	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. *Annals of Oncology*, **2011**, 22, 2591-2596	10.3	22
24	Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. *Clinical Chemistry*, **2010**, 56, 1148-57	5.5	58
23	Adjuvant docetaxel for high-risk, node-negative breast cancer. *New England Journal of Medicine*, **2010**, 363, 2200-10	59.2	149
22	Current perspectives of treatment of ductal carcinoma in situ. *Cancer Treatment Reviews*, **2010**, 36, 507-17	14.4	14
21	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. *Tumor Biology*, **2010**, 31, 171-80	2.9	54
20	Quality of life during treatment in young women with breast cancer. *Breast Cancer Research and Treatment*, **2010**, 123 Suppl 1, 75-7	4.4	12
19	Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems. *Breast Journal*, **2010**, 16, 134-40	1.2	17
18	18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1551-7	8.8	91
17	Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. *British Journal of Cancer*, **2009**, 100, 442-9	8.7	30
16	Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. *Annals of Oncology*, **2009**, 20, 454-9	10.3	10
15	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. *Cancer Treatment Reviews*, **2008**, 34, 701-9	14.4	18
14	A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. *Clinical Cancer Research*, **2008**, 14, 811-6	12.9	104
13	Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. *Journal of Clinical Oncology*, **2008**, 26, 4746-51	2.2	214
12	The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials. *Clinical Breast Cancer*, **2007**, 7, 764-74	3	3
11	Current controversies in the management of early breast cancer. *Clinical and Translational Oncology* , **2007**, 9, 375-84	3.6	3
10	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. *Cancer Treatment Reviews*, **2007**, 33, 474-83	14.4	14

9	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
8	Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 715-21	4	66
7	Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. *Oncology*, **2004**, 66, 388-94	3.6	43
6	Gender, age, socio-demographic and lifestyle factors associated with major dietary patterns in the Spanish Project SUN (Seguimiento Universidad de Navarra). *European Journal of Clinical Nutrition*, **2003**, 57, 285-92	5.2	136
5	Scintigraphic evolution of a breast cancer with Tc-99m MIBI scintimammography. *Clinical Nuclear Medicine*, **2000**, 25, 701-3	1.7	
4	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. *Breast Cancer Research and Treatment*, **1998**, 51, 109-19	4.4	89
3	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. *Journal of Pathology*, **1998**, 184, 265-71	9.4	44
2	Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. *Journal of Pathology*, **1997**, 182, 160-6	9.4	54
1	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. *British Journal of Cancer*, **1996**, 74, 1126-31	8.7	58